Comparison of High Responder Inhibitor Frequency in Recent Studies of Previously Untreated Patients with Hemophilia A

• References

• 1 Gruppo R, Bray GL, Schroth P, Perry M, Gomperts ED. Safety and immunogenicity of recombinant factor VIII (Recombinate™) in previously untreated patients (PUPs): A 6.5-year update.. Thromb Haemost 1998 (Suppl.) 162. (Abstract).
• 2 Lusher J, Arkin S, Abildgaard CF, Hurst D. Recombinant FVIII (Kogenate) treatment of previously untreated patients (PUPs) with hemophilia A: Update of safety, efficacy and inhibitor development after seven study years.. Thromb Haemost 1998 (Suppl.) 162. (Abstract).
• 3 Lusher J, Salzman PM. et al. Viral safety and inhibitor development associated with factor VIIIC ultra-purified from plasma in hemophiliacs previously unexposed to factor VIIIC concentrates.. Sem Hematol 1990; 27: 1-7.
• 4 Ehrenforth S, Kreuz W, Scharrer I, Linde R, Funk M, Güngör T, Krackhardt B, Kornhuber B. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs.. Lancet 1992; 339: 594-8.
• 5 Addiego J, Kasper C, Abildgaard C, Hilgartner M, Lusher J, Glader B, Aledort L. Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIII.. Lancet 1993; 342: 462-4.
• 6 de Biasi R, Rocino A, Papa ML, Salerno E, Mastrullo L, De Biasi D. Incidence of factor VIII inhibitor development in hemophilia A patients treated with less pure plasma derived concentrates.. Thromb Haemost 1994; 71: 544-7.